Table 1.
The details of the included RCTs
| Study | Center | Enrolled patients | Sample size, n IVUS/Control | Follow-Up | MACE | Type of DES | Study quality |
|---|---|---|---|---|---|---|---|
| RESET trial (2013) | Multicenter | Long lesions | 269/274 | 1 year | Cardiac death, MI, TVR, or ST | Zotarolimus/Everolimus | 5 |
| IVUS-XPL trial (2016) | Multicenter | Long lesions | 700/700 | 1 year | Cardiac death, MI, or TLR | Everolimus | 5 |
| CTO-IVUS trial (2015) | Multicenter | CTO | 201/201 | 1 year | Cardiac death, MI, or TVR | Zotarolimus/Nobori biolimus | 5 |
| Air-CTO trial (2015) | Multicenter | CTO | 115/115 | 2 years | Death, MI, TLR, ST | First/Second-generation | 4 |
| Tan et al. (2015) | Single center | Unprotected LM | 61/62 | 2 years | Death, MI, or TLR | Sirolimus | 2 |
| Liu et al. (2019) | Single center | Unprotected LM | 167/169 | 1 year | Cardiac death, MI, and TVR | First /Second-generation | 3 |
| Home DES IVUS (2010) | Single center | Complex lesions | 105/105 | 18 months | Death, MI, TLR | TAXUS/CYPHER | 4 |
| AVIO trial (2013) | Multicenter | Complex lesions | 142/142 | 2 years | Cardiac death, MI, TVR | NA | 4 |
| Zhang et al. (2016) | Single center | De novo lesion in a small vessel (diameter 2.25–2.75 mm) | 42/42 | 1 year | Cardiac death, MI, or TVR | NA | 2 |
Note: The qualities of included randomized trials were assessed by the Jadad score. CTO - chronic total occlusion; DES - drug-eluting stent; IVUS - intravascular ultrasound; LM - left main disease; MACE - major averse cardiovascular events; MI - myocardial infarction; mm - millimeter; n - number; NA - not available; RCT - randomized controlled trials; ST - stent thrombosis; TLR - target lesion revascularization; TVR - target vessel revascularization